ABBV vs AIZ Stock Comparison

Scores Breakdown

Metric	ABBV	AIZ
📈 Growth	26/30	26/30
💰 Profitability	18/20	14/20
🏦 Financial Health	6/20	15/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	8/10	3/10
Overall Score	64/100	74/100

Side-by-Side Summaries

ABBV Analysis	AIZ Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits. 💰 Margins & Cash Flow Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters. 🛡️ Balance Sheet & Liquidity Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity. ⚠️ Key Drivers & Risks Drivers: Steady premium revenue growth; improving operating leverage. Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

ABBV Analysis

AIZ Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits.

💰 Margins & Cash Flow

Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity.

⚠️ Key Drivers & Risks

Drivers: Steady premium revenue growth; improving operating leverage.
Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"